Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF ± RBV) and ombitasvir/ paritaprevir/ritonavir plus dasabuvir (OPrD) ± RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical practice.
individuals receiving LDV/SOF is limited. LDV concentrations are decreased in the setting of PPI use [13] . Observational cohorts of predominantly HCV-monoinfected patients have been inconsistent, demonstrating decreased SVR rates with PPI use in some cohorts but not others [14, 15] . Presently, the extent of clinically meaningful changes in renal function in HIV/HCV-coinfected patients receiving tenofovir and protease inhibitors (PIs) is unknown. LDV increases the maximum plasma concentration of tenofovir by 47%-64% when coadministered with ritonavir-boosted atazanavir or darunavir [13, 16] . The ION-4 study of LDV/SOF in HIV/HCV coinfection excluded participants on PI-containing therapy [5] ; thus, real-world use of tenofovir and PI-containing regimes is needed to inform treatment decisions.
Our objectives were to characterize SVR rates in HIV/HCVcoinfected veterans receiving LDV/SOF-and ombitasvir/paritaprevir/ritonavir plus dasabuvir (OPrD)-based regimens, to identify predictors of SVR, and to characterize changes in renal function, particularly in those receiving LDV/SOF-containing regimens in a real-world cohort of HIV/HCV-coinfected veterans.
MATERIALS AND METHODS
This was an observational intent-to-treat (ITT) cohort analysis of HIV/HCV GT1-coinfected veterans receiving LDV/SOF with or without (±) ribavirin (RBV) or OPrD ± RBV from any Veterans Affairs (VA) facility. This study used data from the VA's Clinical Case Registry for HCV, an extract of the VA electronic medical record for HCV-infected veterans seen at all VA medical facilities [17] .
Eligible subjects included all HIV/HCV GT1-infected veterans from any VA facility nationwide who initiated VA-prescribed LDV/SOF ± RBV or OPrD ± RBV by 30 September 2015 with an end of treatment (EOT) by 15 January 2016 and a days' supply of >1 week and ≤91 days. For patients who received multiple courses of therapy, only the first course was included. Regimen selection and timing of follow-up visits and laboratory testing was at the discretion of the provider as patients were treated in routine practice. Patients were excluded if they had a baseline HCV RNA ≤1000 IU/mL (n = 32), had a liver transplant (n = 1), or received OPrD alone and had subtype 1a (n = 3).
Treatment Outcome
Patients were considered to have SVR if they had HCV RNA results below the limit of quantification on all HCV RNA tests after the EOT including at least 1 test ≥10 weeks after the EOT; a 10-week time point was used to account for the realities of variability in timing of laboratory testing in clinical practice. Patients were categorized as no SVR if they had HCV RNA above the limit of quantification after the EOT and no subsequent test ≥10 weeks after EOT, had no HCV RNA testing after the EOT and HCV RNA above the limit of quantification on their last HCV RNA test while on treatment, or died on treatment or within 10 weeks of the EOT. Patients with HCV RNA below the limit of quantification on their last HCV viral load test while on treatment or after the EOT, but no test ≥10 weeks after the EOT were excluded from the SVR analysis. The EOT was calculated as the last day covered by prescriptions of LDV/SOF or OPrD using the dates the medication was dispensed and the days' supply. HCV RNA was categorized as above or below the lower limit of quantification, of which 98% of sites utilized assays with a lower limit of quantification of ≤15 IU/mL. Patients were followed from the initiation of LDV/SOF ± RBV or OPrD ± RBV through 30 April 2016. Patients were considered to have completed 12 weeks of LDV/SOF ± RBV or OPrD ± RBV if they received between 77 and 91 days of medication.
Control Variables
Demographic and other baseline variables were determined at the time of treatment initiation and included age, sex, race, cirrhosis (defined by International Classification of Diseases, Ninth Revision [ICD-9] codes), history of decompensated liver disease (defined by ICD-9 codes for esophageal variceal hemorrhage, hepatic coma, hepatorenal syndrome, or spontaneous bacterial peritonitis), PPI prescription, and prior HCV antiviral treatment experience. Prior virologic response was based on the most recent VA course of HCV antiviral treatment. Because HIV antiretroviral prescriptions are generally filled for 90 days in VA, the HIV antiretroviral regimen for a patient was identified as including any antiretrovirals filled in both the 89 days before and the 89 days after start of HCV treatment or any antiretrovirals filled on the date of starting HCV treatment. Patients with no antiretrovirals meeting these criteria are categorized as "unstable/none" for HIV antiretroviral regimen.
Baseline values for height and weight were used to calculate body mass index (BMI) and the baseline laboratory tests for alanine aminotransferase, aspartate aminotransferase, creatinine, platelets, HCV RNA, HIV viral load, and CD4 count were defined as the value within 1 year before and closest to the HCV treatment start date. IL28B polymorphism and HCV GT1 subtype were determined from the most recent result. Subtype 1a included patients with reported results of 1a, mixed 1a/1b, or 1 with subtype unspecified. Maximum creatinine change was calculated as the maximum change in creatinine from the baseline creatinine until 7 days after the EOT. For all comparisons, a P value <.05 was considered statistically significant. All analyses were performed using R version 3.1 (R Foundation for Statistical Computing, Vienna, Austria).
The protocol was approved by the Stanford University Institutional Review Board and the VA Palo Alto Health Care System Research and Development Committee.
RESULTS
In total, 996 patients with HIV/HCV GT1 infection initiated LDV/SOF ± RBV or OPrD ± RBV treatment at 126 VA facilities. Baseline characteristics for the cohort by regimen appear in Table 1 . As this was a real-world cohort with no restrictions on antiretroviral regimen, a wide variety of antiretroviral regimens were identified, particularly among patients receiving LDV/SOF ± RBV (n = 895). SVR results were available for 90.9% (905/996) of patients in the cohort, including 5 patients who died while on treatment or shortly after who were categorized as no SVR. There were 91 patients whose last HCV RNA was undetectable, but occurred while still on treatment (n = 30) or <10 weeks after the EOT (n = 61), who were excluded from the SVR analysis. Fifty patients had an undetectable HCV RNA obtained 10-11 weeks after the EOT and were included in the SVR analysis.
Overall, among 905 HIV/HCV GT1-coinfected patients, 90.9% (823/905) achieved SVR ( Table 2 ). Among 685 LDV/SOF patients and 131 LDV/SOF + RBV patients, 92.1% (631/685) and 86.3% (113/131), respectively, achieved SVR; the SVR rates were 88.9% (24/27) for OPrD and 88.7% (55/62) for OPrD + RBV. In the overall cohort and for patients who received LDV/ SOF, SVR rates differed statistically based on the presence of cirrhosis. No statistically significant differences in SVR were observed according to baseline patient characteristics among patients receiving LDV/SOF + RBV, OPrD, or OPrD + RBV, though there were few patients in the OPrD ± RBV subgroups to detect differences.
Rates of response were similar in patients receiving various HIV antiretroviral regimens. No difference in SVR was observed in African Americans receiving LDF/SOF ± Characteristic Genotype 1 (N = 996) LDV/SOF (n = 757) LDV/SOF + RBV (n = 138) OPrD (n = 28) OPrD + RBV (n = 73) Detectable (<15 IU/mL) 66 (7) 51 (7) 11 (9) 1 (5) 3 (5) Detectable (≥15 IU/mL) 169 (19) 129 (19) 19 (15) In multivariate analysis, the only significant independent predictor of SVR in the main ITT model was cirrhosis (odds ratio
[OR], 0.51 [95% confidence interval {CI}, .31-.87]; P = .01) ( Table 4 ). The use of LDV/SOF + RBV was associated with a statistically significant increased risk of non-SVR in those who completed 12 weeks of therapy (OR, 0.42 [95% CI, .18-.97]; P = .03), and there was a similar nonsignificant trend in both ITT models. Similarly, there was a borderline statistically significant finding of HCV RNA >6 million IU/mL associated with non-SVR in the ITT model including major antiretroviral regimens and similar nonsignificant trends in the other models. Age, race, CD4, PPI use, treatment experience, BMI, GT1 subtype, and HCV treatment regimen did not predict SVR. In models limited to patients receiving 12 weeks of treatment, cirrhosis no longer predicted SVR (OR, 0.63 [95% CI, .31-1.29]; P = .19). In additional sensitivity analysis, use of HIV PI-based or NNRTI-based antiretroviral regimens compared to use of INSTI-based regimens was not associated with a difference in the odds of achieving SVR.
Median baseline creatinine values did not differ among the 4 regimens ( Table 1) Figure 1 ).
DISCUSSION
In this large real-world cohort of HIV/HCV-coinfected veterans, SVR rates were 92.1% for LDV/SOF, 86.3% for LDV/SOF + RBV, 88.9% for OPrD, and 88.7% for OPrD + RBV. Limited to those who completed 12 weeks of treatment, SVR rates were even higher. SVR rates for HIV/HCV coinfected African Americans, who represented 67% of this cohort, did not differ from nonAfrican Americans. Of note, SVR rates in African Americans who received EFV-based therapy and LDV/SOF did not differ from SVR rates in non-African Americans on EFV-based therapy and LDV/SOF. The only predictor of treatment failure in multivariate analysis was cirrhosis. PPI prescriptions were not associated with reduced SVR in this HIV/HCV coinfection cohort. In the interferon era, African American race was associated with decreased SVR rates [18] , in part because of a high prevalence of the IL28B CT/TT genotypes that conferred reduced interferon susceptibility in persons of African descent [19] . More recently, in an integrated analysis of all phase 3 LDV/SOF studies, African American race was associated with decreased SVR rates in those receiving 8-week regimens of LDV/SOF [11] . A VA real-world cohort that included HCV-monoinfected and HIV/HCV-coinfected patients showed similar results in African Americans [12] . In a HIV/HCV coinfection clinical trial, Naggie and colleagues found that, when compared to non-black patients, black patients had lower SVR rates (90% vs 99%, respectively; P < .001) and higher relapse rates [5] . Eight of the 10 black patients failing treatment received EFV. Ledipasvir plasma levels, however, were equivalent in those receiving EFV vs other antiretroviral-containing regimens and in those with or without SVR. In our larger cohort of HIV/HCV-coinfected African American veterans, there was no impact of African American race on SVR rates in patients receiving LDV/SOF. Furthermore, we found equivalent SVR rates in African Americans on EFV-and non-EFV-based therapy (92.5% and 91.0%, respectively).
In those who received LDV/SOF, there was no difference in creatinine change among those receiving tenofovir and non-tenofovir-containing regimens, including those also receiving PIs. This is the first real-world study to report renal outcomes of HIV/HCV-coinfected patients and reassures providers that in patients with normal renal function, tenofovir/ PI-containing regimens can be used with LDV/SOF. This may have positive implications for velpatasvir which also increases tenofovir concentrations.
Limitations to our study included the predominantly male population, thus limiting generalizability to women. Few patients received OPrD, likely a result of drug-drug interaction concerns; thus, interpretations are limited in this group. In addition, there may be other unidentified cofounders not included in the multivariate models. The finding of reduced odds of SVR with LDV/SOF + RBV compared to LDV/SOF suggests that providers appropriately identified patients as less likely to respond and opted for a more intensive regimen with RBV. As such, the reduced odds of SVR with LDV/SOF + RBV likely does not reflect an intrinsic increased risk of treatment failure with LDV/SOF + RBV but rather that receipt of this regimen identifies patients less likely to respond, even controlling for the other factors included in the models which included the diagnosis of cirrhosis. Inherent to large administrative health record analyses, we were unable to assess prescriber intent for duration of therapy and reasons for discontinuation. We did not assess 24-week regimens, although they are used rarely in VA. We could not assess the impact of IL28B status or baseline resistance associated variants as these were performed on very few patients during this time. Finally, we could not assess the impact of HIV viral load on HCV treatment response, as the majority of patients were HIV virologically suppressed.
In conclusion, SVR rates were comparable to those of clinical trials in this large real-world cohort of HCV treatment-naive and treatment-experienced HIV/HCV-coinfected veterans receiving 12 weeks of LDV/SOF or OPrD-based regimens. African Americans had SVR rates comparable to non-African Americans, including in those receiving EFV-based regimens. In multivariate analysis, only cirrhosis was associated with reduced odds of SVR. There was no clinically meaningful difference in creatinine change in those receiving tenofovir vs non-tenofovir-containing antiretroviral regimens, including in those receiving tenofovir/PI-containing regimens. Data from this cohort provide further evidence of the efficacy of DAAbased therapy in HIV/HCV coinfection, particularly in African Americans, and reassurance on the use of tenofovir-containing regimens when coadministered with LDV/SOF.
